{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:39:07Z","timestamp":1790627947307,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bacteremia caused by MRSA with reduced vancomycin susceptibility (MRSA-RVS) frequently resulted in treatment failure and mortality. The relation of bacterial factors and unfavorable outcomes remains controversial. We retrospectively reviewed clinical data of patients with bacteremia caused by MRSA with vancomycin MIC\u2009=\u20092\u2009mg\/L from 2009 to 2012. The significance of bacterial genotypes, <jats:italic>agr<\/jats:italic> function and heterogeneous vancomycin-intermediate <jats:italic>S<\/jats:italic>. <jats:italic>aureus<\/jats:italic> (hIVSA) phenotype in predicting outcomes were determined after clinical covariates adjustment with multivariate analysis. A total of 147 patients with mean age of 63.5 (\u00b118.1) years were included. Seventy-nine (53.7%) patients failed treatment. Forty-seven (31.9%) patients died within 30 days of onset of MRSA bacteremia. The Charlson index, Pitt bacteremia score and definitive antibiotic regimen were independent factors significantly associated with either treatment failure or mortality. The hVISA phenotype was a potential risk factor predicting treatment failure (adjusted odds ratio 2.420, 95% confidence interval 0.946\u20136.191, <jats:italic>P<\/jats:italic>\u2009=\u20090.0652). No bacterial factors were significantly associated with 30-day mortality. In conclusion, the comorbidities, disease severity and antibiotic regimen remained the most relevant factors predicting treatment failure and 30-day mortality in patients with MRSA-RVS bacteremia. hIVSA phenotype was the only bacterial factor potentially associated with unfavorable outcome in this cohort.<\/jats:p>","DOI":"10.1038\/s41598-018-26277-9","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T14:44:07Z","timestamp":1526309047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility"],"prefix":"10.1038","volume":"8","author":[{"given":"Chien-Chang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Len","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yhu-Chering","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shian-Sen","family":"Shie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jwu-Ching","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pang-Hsin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsi","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-2461","authenticated-orcid":false,"given":"Chih-Jung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"26277_CR1","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1128\/AAC.00425-13","volume":"57","author":"M Matsuo","year":"2013","unstructured":"Matsuo, M., Cui, L., Kim, J. & Hiramatsu, K. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob Agents Chemother 57, 5843\u20135853 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"26277_CR2","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1128\/JCM.00582-08","volume":"46","author":"MJ Rybak","year":"2008","unstructured":"Rybak, M. J. et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 46, 2950\u20132954 (2008).","journal-title":"J Clin Microbiol"},{"key":"26277_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PGP Charles","year":"2004","unstructured":"Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P. & Grayson, M. L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38, 448\u2013451 (2004).","journal-title":"Clin Infect Dis"},{"key":"26277_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jmii.2011.11.006","volume":"45","author":"Y-C Yeh","year":"2012","unstructured":"Yeh, Y.-C., Chiu, S.-K., Yang, Y.-S., Wang, Y.-C. & Lin, J.-C. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect 45, 214\u2013220 (2012).","journal-title":"J Microbiol Immunol Infect"},{"issue":"Suppl 2","key":"26277_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0924-8579(08)70002-5","volume":"31","author":"IM Gould","year":"2008","unstructured":"Gould, I. M. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31(Suppl 2), 1\u20139 (2008).","journal-title":"Int J Antimicrob Agents"},{"key":"26277_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","volume":"28","author":"RKC Fong","year":"2009","unstructured":"Fong, R. K. C., Low, J., Koh, T. H. & Kurup, A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 28, 983\u2013987 (2009).","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"26277_CR7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/jac\/dks131","volume":"67","author":"K-H Park","year":"2012","unstructured":"Park, K.-H. et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother 67, 1843\u20131849 (2012).","journal-title":"J Antimicrob Chemother"},{"key":"26277_CR8","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1128\/AAC.01365-08","volume":"53","author":"KC Horne","year":"2009","unstructured":"Horne, K. C. et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 53, 3447\u20133452 (2009).","journal-title":"Antimicrob Agents Chemother"},{"key":"26277_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal, S. J., Lodise, T. P. & Paterson, D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54, 755\u2013771 (2012).","journal-title":"Clin Infect Dis"},{"key":"26277_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.01133-10","volume":"55","author":"SJ van Hal","year":"2010","unstructured":"van Hal, S. J. & Paterson, D. L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 55, 405\u2013410 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"26277_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/infdis\/jir270","volume":"204","author":"NE Holmes","year":"2011","unstructured":"Holmes, N. E. et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 204, 340\u2013347 (2011).","journal-title":"J Infect Dis"},{"key":"26277_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jac\/dkt395","volume":"69","author":"C-J Chen","year":"2014","unstructured":"Chen, C.-J., Lin, M.-H., Shu, J.-C. & Lu, J.-J. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing. J Antimicrob Chemother 69, 349\u2013354 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"26277_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P. & Grayson, M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23, 139 (2010).","journal-title":"Clin Microbiol Rev"},{"key":"26277_CR14","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/jac\/dkr169","volume":"66","author":"R Khatib","year":"2011","unstructured":"Khatib, R. et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 66, 1594\u20131599 (2011).","journal-title":"J Antimicrob Chemother"},{"key":"26277_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1086\/596629","volume":"199","author":"Y Maor","year":"2009","unstructured":"Maor, Y. et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 199, 619\u2013624 (2009).","journal-title":"J Infect Dis"},{"key":"26277_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-159","volume":"10","author":"J-L Wang","year":"2010","unstructured":"Wang, J.-L., Wang, J.-T., Sheng, W.-H., Chen, Y.-C. & Chang, S.-C. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC\u2009=\u20092 mg\/L, by the broth microdilution method. BMC Infect Dis 10, 159 (2010).","journal-title":"BMC Infect Dis"},{"key":"26277_CR17","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu, C. et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52, e18\u201355 (2011).","journal-title":"Clin Infect Dis"},{"key":"26277_CR18","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/cid\/cit112","volume":"56","author":"KP Murray","year":"2013","unstructured":"Murray, K. P. et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration 1\u2009mg\/L: a matched cohort study. Clin Infect Dis 56, 1562\u20131569 (2013).","journal-title":"Clin Infect Dis"},{"key":"26277_CR19","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1099\/mic.0.2007\/011874-0","volume":"154","author":"KE Traber","year":"2008","unstructured":"Traber, K. E. et al. agr function in clinical Staphylococcus aureus isolates. Microbiology 154, 2265\u20132274 (2008).","journal-title":"Microbiology"},{"key":"26277_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jac\/dkn520","volume":"63","author":"SN Leonard","year":"2009","unstructured":"Leonard, S. N., Rossi, K. L., Newton, K. L. & Rybak, M. J. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 63, 489\u2013492 (2009).","journal-title":"J Antimicrob Chemother"},{"key":"26277_CR21","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1128\/JCM.00776-06","volume":"44","author":"Y-C Huang","year":"2006","unstructured":"Huang, Y.-C., Su, L.-H., Wu, T.-L. & Lin, T.-Y. Changing molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates from a teaching hospital in Northern Taiwan. J Clin Microbiol 44, 2268\u20132270 (2006).","journal-title":"J Clin Microbiol"},{"key":"26277_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1086\/313461","volume":"29","author":"G Lina","year":"1999","unstructured":"Lina, G. et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29, 1128\u20131132 (1999).","journal-title":"Clin Infect Dis"},{"key":"26277_CR23","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1128\/JCM.40.11.4060-4067.2002","volume":"40","author":"P Gilot","year":"2002","unstructured":"Gilot, P., Lina, G., Cochard, T. & Poutrel, B. Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis. J Clin Microbiol 40, 4060\u20134067 (2002).","journal-title":"J Clin Microbiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26277-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:30:34Z","timestamp":1671600634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26277-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26277"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26277-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"14 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7868"}}